Presymptomatic studies in genetic frontotemporal dementia  by Rohrer, J.D. et al.
International meeting of the French society of neurology 2013
Presymptomatic studies in genetic frontotemporal
dementia
E´tudes pre´symptomatiques dans les de´mences
frontotemporales ge´ne´tiques
J.D. Rohrer *, J.D. Warren, N.C. Fox, M.N. Rossor
Dementia Research Centre, UCL Institute of Neurology, University College London, Queen Square,
London, WC1N 3BG, UK
r e v u e n e u r o l o g i q u e 1 6 9 ( 2 0 1 3 ) 8 2 0 – 8 2 4
i n f o a r t i c l e
Article history:
Received 8 June 2013
Accepted 1 July 2013
Available online 4 September 2013
Keywords:
Frontotemporal dementia
Primary progressive aphasia
Progranulin
Tau
C9orf72
Mots cle´s :
De´ge´ne´rescence lobaire frontotem-
porale
De´mence frontotemporale
Aphasie progressive primaire
Progranuline
MAPT
C9ORF72
a b s t r a c t
Approximately 20% of patients with the neurodegenerative disorder frontotemporal demen-
tia (FTD) have an autosomal dominant pattern of inheritance. Genetic FTD is caused by
mutations in three genes in most cases (progranulin, microtubule-associated protein tau
and chromosome 9 open reading frame 72) although a number of other genes are rare
causes. Studies of other neurodegenerative diseases have shown imaging and biomarker
evidence of disease onset many years prior to the development of symptoms. Similar
studies in genetic FTD are now revealing evidence of a series of presymptomatic changes,
initially in plasma biomarkers followed by MR imaging abnormalities of functional and
structural connectivity and then grey matter atrophy. Lastly, neuropsychometric tests
become abnormal in proximity to the onset of symptoms. Such studies have been relatively
small until now but research centres with an expertise in genetic FTD are now forming
consortia such as the Genetic Frontotemporal Dementia Initiative (GenFI) to create larger
cohorts that can form the basis of future clinical trials.
# 2013 Elsevier Masson SAS. All rights reserved.
r e´ s u m e´
Les de´mences frontotemporales (DFT), dans environ 20 % des cas, re´sultent d’un
mode de transmission autosomique dominant. Les trois causes ge´ne´tiques les plus
fre´quentes sont des mutations des ge`nes GRN, MAPT et des expansions hexanucle´oti-
diques au sein du ge`ne C9orf72, alors que d’autres ge`nes sont plus rarement implique´s.
Des e´tudes dans d’autres maladies neurode´ge´ne´ratives ont montre´ que des marqueurs
biologiques et d’imagerie du de´but de la maladie pre´ce`dent de plusieurs anne´es les
premiers symptoˆ mes. Des e´tudes similaires concernant les formes ge´ne´tiques des
DFT mettent actuellement en e´vidence des modifications pre´symptomatiques, initiale-
ment des biomarqueurs plasmatiques, suivies des modifications en imagerie de la
connectivite´ fonctionnelle et structurelle puis des signes d’atrophie de la substance
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http://dx.doi.org/10.1016/j.neurol.2013.07.010ances aux tests neuropsychologiques deviennent anormales
du de´but des symptoˆ mes. Ces e´tudes restent peu nombreusess reserved.
mais les centres ayant une expertise dans la ge´ne´tique des DFT se regroupent actuel-
lement en consortium tel que l’Initiative pour la Ge´ne´tique des De´mences FrontoTem-
porales (GenFI) afin de disposer de larges cohortes qui serviront de base au
de´veloppement des futurs essais cliniques.
# 2013 Elsevier Masson SAS. Tous droits re´serve´s.
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order usually presenting with either behavioural or language
impairment, although it has significant overlap with motor
neurone disease (MND) and the atypical parkinsonian dis-
orders (Seelaar et al., 2011). Around 20% of patients within the
FTD spectrum have an autosomal dominant pattern of
inheritance with mutations in the genes progranulin (GRN),
microtubule-associated protein tau (MAPT) and chromosome
9 open reading frame (C9orf72) being the commonest causes
(Rohrer et al., 2009; Rohrer and Warren, 2011). These each
account for about 5–10% of all FTD cases although there is
geographical variability, e.g. in a US series, C9orf72 expansions
were the most common cause (7% of all FTD, compared to 5%
GRN and 4% MAPT) (Dejesus-Hernandez et al., 2011) whereas in
a Dutch series, MAPT mutations were the most common cause
(10% of all FTD, compared to 9% C9orf72 and 7% GRN) (Simo´n-
Sa´nchez et al., 2012), and in a UK series, the frequency of
mutations in each of the genes was approximately equal (7%
C9orf72, 7% GRN, 6% MAPT) (Mahoney et al., 2012). Mutations in
other genes (VCP, CHMP2B, FUS, TARBP, DCTN1 and SQSTM1)
have been described as causing a disorder within the FTD
spectrum but occur with a very low frequency (Rohrer and
Warren, 2011; Rubino et al., 2012).
GRN, MAPT and C9orf72 mutations can all cause behaviou-
ral variant FTD and this is the most common presenting
syndrome for each of the genes (Rohrer and Warren, 2011;
Dejesus-Hernandez et al., 2011; Renton et al., 2011). However,
there are other clinical syndromes that are seen more
frequently in association with one gene rather than another.
MND is seen commonly in association with expansions in
C9orf72 (although can rarely occur with GRN mutations) whilst
primary language impairment (usually a progressive non-
fluent aphasia, PNFA) is seen with GRN mutations (and rarely
with expansions in C9orf72). Parkinsonism may be seen with
any of the mutations with a variable phenotype, sometimes
very similar to idiopathic Parkinson’s disease (in MAPT
mutations), in other cases, a corticobasal syndrome (with
GRN or, less commonly, MAPT mutations), and more rarely a
progressive supranuclear palsy syndrome (with MAPT muta-
tions) (Rohrer and Warren, 2011).
From a neuroimaging perspective, patients with GRN
mutations tend to have an asymmetrical pattern of atrophy
compared to the more symmetrical pattern seen in MAPT and
C9orf72 mutations (Rohrer et al., 2010; Whitwell et al., 2012).
Early areas of involvement are the temporal, inferior frontal
and inferior parietal lobes in GRN mutations and the
anteromedial temporal and orbitofrontal lobes in MAPT
mutations (Rohrer et al., 2010; Whitwell et al., 2012). C9orf72
expansions have a more variable pattern of cortical atrophy
(although usually frontotemporal predominant) with some
studies suggesting that subcortical (particularly thalamic) andcerebellar atrophy are also seen (Mahoney et al., 2012; Rohrer
and Rosen, 2013).
More detailed reviews of the clinical and neuroimaging
features of symptomatic patients with genetic FTD are
described elsewhere (Rohrer and Warren, 2011; Van Swieten
and Heutink, 2008; Van Swieten and Spillantini, 2007). This
paper reviews studies of those siblings and children of
patients with genetic FTD who are currently clinically well
but are at a 50% risk of developing a disorder within the FTD
spectrum, often termed presymptomatic or ‘at-risk’ genetic
FTD.
1. Why study presymptomatic genetic
frontotemporal dementia?
Whilst there are currently no treatments that can delay the
onset or prevent the progression of genetic FTD, there are
promising avenues for treatment, particularly for GRN
mutations where a uniform disease mechanism of loss of
progranulin function operates in all mutation carriers. Drugs
including chloroquine, nimodipine and vorinostat have been
shown to increase progranulin concentration (Capell et al.,
2011; Cenik et al., 2011) suggesting their use in future clinical
trials. Ideally, therapies would be instituted when the
minimum of irreversible neuronal loss has occurred. This
makes trial design challenging and increases the importance
of biomarkers in selecting suitable subjects and in monitoring
progression, However, despite having potential disease-
modifying therapies there are still no biomarkers of genetic
FTD that can confidently predict when disease-modifying
therapy should be initiated or how the response to it should
be monitored. Evidence from other neurodegenerative disea-
ses such as familial Alzheimer’s disease shows that there
are changes in a number of biomarkers many years before
symptom onset (Bateman et al., 2012) suggesting that the ideal
time for treating these disorders is likely to be prior to clinical
presentation. The identification of robust biomarkers in
genetic FTD that are indicative of disease onset and progres-
sion are therefore prerequisites for any disease-modifying
therapy trial.
2. What do we know about presymptomatic
genetic frontotemporal dementia currently?
A number of studies have examined presymptomatic genetic
FTD although the majority of these have been either individual
case reports or relatively small case series. Whilst a few have
shown presymptomatic changes in neuropsychometric test-
ing of executive function and social cognition (Janssen et al.,
r e v u e n e u r o l o g i q u e 1 6 9 ( 2 0 1 3 ) 8 2 0 – 8 2 48222005; Rohrer et al., 2008), most have not shown any cognitive
changes.
Prior to manifesting neuropsychometric abnormalities and
several years before disease onset, a number of structural T1
MR imaging studies have now shown evidence of grey matter
atrophy. One study examined a patient with familial FTLD-U
(now known to be associated with a GRN mutation) and
showed evidence of very focal left frontal lobe atrophy
affecting the pars opercularis about two years prior to the
onset of PNFA (Janssen et al., 2005). Another single case report
of a subject with a GRN mutation who later developed PNFA
showed evidence of early left hemisphere atrophy, particu-
larly in the frontal lobe but also in the middle and inferior
temporal gyri and angular gyrus, at least eighteen months
prior to symptom onset (Rohrer et al., 2008). This was
consistent with a study of four presymptomatic GRN mutation
carriers from a PNFA family who had a similar pattern of
atrophy and also hypometabolism on FDG-PET scanning
(Cruchaga et al., 2009). MAPT mutations have been studied
less frequently, although one study did show presymptomatic
hippocampal atrophy (Miyoshi et al., 2010).
Studies using other imaging modalities have identified
presymptomatic changes that appear to occur earlier than
grey matter atrophy. A small study of at-risk GRN mutation
carriers (n = 4) showed no evidence of grey matter atrophy but
using diffusion tensor imaging (DTI) did show reduced
fractional anisotropy (FA) in the left uncinate fasciculus and
inferior fronto-occipital fasciculus compared with controls
(Borroni et al., 2008). A larger DTI study of presymptomatic
GRN mutation carriers (n = 27) also showed decreased FA in the
inferior fronto-occipital fasciculus (on the right) as well as
involvement of the right anterior and superior corona radiata,
anterior thalamic radiation, superior longitudinal fasciculus,
forceps minor and internal capsule (Dopper et al., 2013). In
comparison, presymptomatic MAPT mutation carriers (n = 9)
showed widespread decreased FA (and also increased mean,
axial and radial diffusivity) throughout frontotemporal white
matter tracts.
This same study also examined changes in resting state
functional MRI (RS-fMRI) in presymptomatic GRN and MAPT
mutation carriers. Studies of RS-fMRI have been used to
elucidate a series of coherent large-scale brain networks, the
best described being the ‘default mode network’, a set of
regions centred around the posterior cingulate, precuneus,
lateral parietal and temporal lobes, and medial prefrontal
cortex that routinely decrease their activity during atten-
tion-demanding tasks. In FTD, the network that has been
studied in the most detail is a ‘salience network’ centred
around the fronto-insula cortex and dorsal anterior cingu-
late. In the study by Dopper et al., no changes were seen in
MAPT mutation carriers but there was reduced connectivity
in the anterior midcingulate cortex (an area within the
salience network) in GRN mutation carriers without any
changes in the posterior cingulate cortex (an area within the
default mode network) (Dopper et al., 2013). This is in
contrast to another study of presymptomatic GRN mutation
carriers which showed increased connectivity in a small
area in the medial prefrontal cortex (which the authors
attribute to the salience network) also without any changes
in other networks (Borroni et al., 2012). Another study ofpresymptomatic MAPT mutation carriers showed reduced
connectivity in parts of the default mode network (lateral
temporal and medial prefrontal cortex) with increased
connectivity in other parts of the default mode network
(medial parietal) and no changes in the salience network
(Whitwell et al., 2011). It remains unclear why there are such
divergent findings in RS-fMRI studies although this may
represent differences in the stage at which carriers were
studied or in the methods used for analysis.
There has been a single study of magnetic resonance
spectroscopy in MAPT mutation carriers showing metabolite
abnormalities several years before the onset of symptoms
(elevated myoinositol/creatine ratio and decreased N-acety-
laspartate/myoinositol ratio) (Kantarci et al., 2010).
There are few established serum or CSF markers of FTD.
Decreased plasma progranulin concentrations are found in
symptomatic patients with GRN mutations but similarly low
levels have also been found in presymptomatic mutation
carriers who are in their 20’s and 30’s and are therefore many
years prior to disease onset (Borroni et al., 2012; Ghidoni et al.,
2012). It remains unclear whether other serum or CSF markers
will be abnormal this early as has been found for a number of
biomarkers in familial Alzheimer’s disease (Bateman et al.,
2012).
In summary, these studies suggest that there is a sequence
of changes seen in different biomarkers of genetic FTD prior to
clinical onset of symptoms: the earliest of these are likely to be
a number of plasma (and CSF) markers (although apart from
plasma progranulin concentration this remains unproven)
followed by markers of functional and structural connectivity,
then grey matter atrophy, and finally mild neuropsychometric
abnormalities in proximity to the first symptoms.
3. How can we take things forward?
Genetic FTD is a rare condition and individual research
centres have only been able to study relatively small numbers
of participants. Further progress is therefore likely to depend
on pooling populations of presymptomatic FTD, which allows
both for a large cohort of individuals and for a range of
different mutations within the same gene to be investigated.
Larger studies also permit a greater understanding of the
natural history of the disorder, from younger at risk subjects
many years before symptom onset through to those subjects
near to the time of conversion to manifest disease (thus
allowing identification of ‘proximity markers’ to symptom
onset). Head-to-head comparison of candidate biomarkers can
be performed investigating whether combined multimodal
indices may be more useful than individual markers, or
whether novel indices should be used e.g. social cognition
tasks that highlight cognitive changes prior to standard
neuropsychometry, or fMRI studies that identify vulnerable
brain networks. With a growing understanding of many
neurodegenerative disorders as nexopathies targeting a
particular network, large studies of genetic FTD will also
provide unique insights into the underlying pathophysiology
of the disease (Warren et al., 2012).
Successful models for multicentre consortia of this kind
have been established for other neurodegenerative diseases
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(DIAN) and the TrackHD consortium for Huntington’s
disease (Bateman et al., 2012; Tabrizi et al., 2009). Based
upon these models the Genetic Frontotemporal dementia
Initiative (GENFI) was set up in 2011 to bring together
research centres across Europe and Canada with an interest
in clinical studies of presymptomatic genetic FTD. There are
currently twelve centres that form the consortium, situated
in the UK, Italy, Holland, Sweden and Canada, with over two
hundred subjects now recruited. Subjects undergo a stan-
dardized clinical and neuropsychological assessment
(including the revised Cambridge Behavioural Inventory
(CBI-R) (Wear et al., 2008), Frontotemporal dementia Rating
Scale (FRS) (Mioshi et al., 2010) and the Uniform Data Set
(UDS) psychometric battery (Morris et al., 2006)) as well as
volumetric T1, DTI, RS-fMRI and arterial spin labeling
perfusion MRI. DNA, RNA, serum and plasma samples are
taken from all subjects and some subjects also have
cerebrospinal fluid collected. A secure online database is
in place for uploading all data in a pseudoanonymised form.
A particular ethical consideration is the recruitment of at
risk subjects without the need for them to have undergone
presymptomatic genetic testing. Protocols are in place to
ensure that testing in those currently unaware of their
genetic status is performed without the knowledge of the
result becoming known either to them or to any clinician
involved in assessing them (unless the subject wishes to
know the result and has gone through a standard clinical
process of genetic counseling). The aim of the study will be to
create a large cohort of presymptomatic at risk genetic FTD
subjects who could take part in clinical trials and who are
studied using a uniform methodological platform and
infrastructure, with the key outcomes being to develop
robust markers of disease onset and stage including those
indicative of optimal time to start disease-modifying therapy
as well as markers of disease progression that can be used as
outcome measures in clinical trials.
We are at a turning point in genetic FTD research where
clinical trials of disease-modifying therapy are now a reality
and it is therefore of the utmost important to have the right
infrastructure in place and the correct biomarkers measured
to ensure the best possible chance that such trials will
succeed.
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